Figure 1. Remdesivir can be metabolized into its active form GS-441524 and target RdRp of coronavirus. (The picture of RdRp is regenerated from the structure of SARS-CoV nsp12 polymerase, PDB: 6NUS.) Figure 2. Scientists were developing the COVID-19 diagnostic kit during the Chinese New Year. Development of rapid, accurate, safe, and convenient detection and diagnosis technologies. Early stage screening is to quickly isolate confirmed patients. Intermediate stage screening can provide basis for precise treatment, and later screening is to establish reliable standards for discharge and desegregation. Specific diagnostic methods should be developed for each of the different stages. Fast screening of safe and effective drugs. In the face of sudden public health safety incidents, the fastest way is to establish treatments to identify drugs already available in drug libraries since their safety has been proved in clinical trials. At the same time, drug efficacy needs to be screened for different stages of the disease. For example, for advanced patients, reducing the cytokine storm may be a major direction. Development of neutralizing antibodies and vaccines. Interdisciplinary participation, including chemical biology, is expected to accelerate the research and development process, for example, how to speed up the adaptive immune response to develop specific IgG antibodies, how to efficiently enrich antibodies from serum, and how to quickly and cost-effectively isolate human B cells and perform single BCR sequencing to facilitate the identification of neutralizing antibodies. Views expressed in this editorial are those of the authors and not necessarily the views of the ACS. This manuscript was written at the end of February 2020, while the WHO declared the novel coronavirus outbreak to be a pandemic on March 11. Hope it will be over soon! This article references 10 other publications.

中文翻译：

---

抗击冠状病毒的爆发。

图 1. 瑞德西韦可代谢为其活性形式 GS-441524，并靶向冠状病毒的 RdRp。（RdRp 的图片是根据 SARS-CoV nsp12 聚合酶的结构重新生成的，PDB：6NUS。）图 2. 科学家在农历新年期间正在开发 COVID-19 诊断试剂盒。发展快速、准确、安全、便捷的检测诊断技术。早期筛查是为了快速隔离确诊患者。中期筛查可以为精准治疗提供依据，后期筛查则是为出院和解除隔离建立可靠的标准。应针对每个不同阶段制定具体的诊断方法。快速筛选安全有效的药物。面对突发的公共卫生安全事件，最快的方法是建立治疗方法，识别药物库中已有的药物，因为它们的安全性已经在临床试验中得到证明。同时，需要针对疾病的不同阶段筛选药物疗效。例如，对于晚期患者来说，减少细胞因子风暴可能是一个主要方向。开发中和抗体和疫苗。包括化学生物学在内的跨学科参与有望加速研发进程，例如如何加快适应性免疫反应以开发特异性IgG抗体，如何高效地从血清中富集抗体，以及如何快速且经济高效地制备抗体。分离人 B 细胞并进行单一 BCR 测序，以促进中和抗体的鉴定。本社论中表达的观点仅代表作者的观点，并不一定代表 ACS 的观点。这篇稿子写于2020年2月底，而世界卫生组织则在3月11日宣布新型冠状病毒疫情为大流行病。希望这一切尽快结束！本文参考了其他 10 篇出版物。